Chinmay Jani

This account is verified. Learn more

@Jani_Chinmay

Chief Fellow @HemOncMiami @univmiami @SylvesterCancer | Former Chief Resident @MountAuburnHosp @MAHIMRes @HarvardMed | NHLMMC Alum| @COVID19nCCC

Joined May 2013

1.8K Following 1.5K Followers 2.2K Posts

Latest posts 5

Chinmay Jani @Jani_Chinmay Oct 29

Leadership is not just about accomplishments - it is about the impact we create and the people we empower along the way!

Having had the privilege of collaborating with @montypal across kidney cancer research and global oncology initiatives, I have witnessed his exceptional commitment to advancing cancer research, mentorship, and supporting the next generation of oncologists.

His vision, experience, and dedication would be tremendous assets to the @ASCO Board!

I strongly encourage all eligible ASCO members to cast their vote for @montypal !

🗳️ asco.org/election

@ASCOTECAG @OncUpdates @oncodaily @OncBrothers @GlopesMd @Latinamd @neerajaiims @JamesFanWu @HemOncFellows @OncoAlert @sawyer_bawek @DrSAHaddad @CancerNetwrk @OncWithGrant @Jonathanwlee23 @FLASCO_ORG @EddieSantosMD @LuisRaezMD @DocOncMD

Sumanta K. Pal, MD, FASCO Verified account @montypal Oct 28

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

View quoted post on X

Chinmay Jani @Jani_Chinmay Oct 23

The FDA has converted the accelerated approval of pembrolizumab (IV) or pembrolizumab and berahyaluronidase alfa-pmph (SC) to traditional approval for patients with previously treated unresectable or metastatic TMB-high solid tumors, with an updated threshold of ≥13 mutations/Mb.

Based on the phase 2 KEYNOTE-158 trial, this approval highlights the evolving role of TMB as a predictive biomarker for immunotherapy and the importance of refining biomarker thresholds based on clinical efficacy data.

Another important step in the convergence of precision medicine and immunotherapy.

Shared my perspectives with @CancerNetwrk ! @SylvesterCancer @GlopesMd @Latinamd @HemOncMiami

cancernetwork.com/view/fda-appro…

www.cancernetwork.com FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors | CancerNetwork The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.

CancerNetwork® Verified account @CancerNetwrk Oct 23

🚨@FDADrugs provides traditional approval to embrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in unresectable or metastatic TMB-H solid tumors.
🔗cancernetwork.com/view/fda-appro…

View quoted post on X

Chinmay Jani @Jani_Chinmay Oct 21

Continuing the trend with @BenBleibergMD !

This year’s @eaonc meeting was even more special, as we both had the opportunity to present our research findings at different committees!

Excited to continue our work in #ThoracicOncology and #PrecisionOncology!

And delighted to welcome @dan_morgen , this fall’s Edith Peterson Mitchell Awardee from @SylvesterCancer @HemOncMiami , to the tradition! 🎉

Chinmay Jani Verified account @Jani_Chinmay Jul 30

When in the Tri-State area for @AACR workshop - how could I miss a mandatory lung cancer collaboration and discussion with incoming faculty at @FoxChaseCancer - @BenBleibergMD ? 🫁🤝

This time, joined by, @DesaiP_Oncdoc, and @chitkaramd !
@ASCOTECAG @SylvesterCancer @HemOncMiami

View quoted post on X

Chinmay Jani @Jani_Chinmay Oct 21

🤖🫁 How reliable is AI in guiding treatment decisions for patients with #NSCLC? Our study @SylvesterCancer in collaboration with @Larvol highlights important gaps in the accuracy of current AI models (60–80%) when providing clinical recommendations.

As AI becomes increasingly integrated into oncology, rigorous validation, clinical oversight, and evidence-based recommendations remain essential.

Grateful to @VJOncology for the opportunity to discuss our findings!
#AI #LungCancer #PrecisionOncology
@GlopesMd @Latinamd @dan_morgen @HemOncMiami

VJ Oncology Verified account @VJOncology Oct 21

How accurate are #AI models at giving clinical advice for #NSCLC without actionable mutations? 🤖 🫁

Chinmay Jani (@Jani_Chinmay) explores results from a study showing that models ranged from 58-60% accurate 🥼

Watch: ow.ly/kJcJ50ZZ2cQ

#Oncology #LCSM #LungCancer @IASLC
View quoted post on X

Chinmay Jani @Jani_Chinmay Oct 21

🫁🧬 Sincere thanks to @eaonc for inviting me back as a former Edith Peterson Mitchell Award recipient to share our ongoing research at @SylvesterCancer.

My talk focused on two important aspects of lung cancer research:
🌍 Understanding the evolving epidemiology and global burden of lung cancer risk factors.
🧬 Exploring how genomic alterations and the tumor immune landscape differ across age groups.

Grateful for the opportunity to share our work and connect with fellow investigators! @GlopesMd @Latinamd @dan_morgen @HemOncMiami @DesaiP_Oncdoc @BenBleibergMD